Preliminary Injunction Against Endo possible $300 million hit

check this out...

Preliminary Injunction Against Endo possible $300 million hit 23-Jun-09 01:46 pm This stock is dead in the water till this is over

I wonder if Endo had any idea that this patch was infringing on the lectec patent. They were just so dang excited about the $100 mill potential in 1999... which is now $700 million annually ........the FDA exclusive approval runs out in 2015....total sales from 1999 through 2015 would be approx $10 billion x 3% = $300 million to Lectec or around $70 a share cash.




( Mentholatum who settled with lectec is also a Japanese owned company In 1974, the giant Japanese pharmaceutical company based in Osaka known as Rohto Pharmaceutical Co. set its eyes on The Mentholatum Company. In August 1975, it acquired the trademark rights to Mentholatum and began to sell the Mentholatum Ointment and Mentholatum Medicated Lip Stick, which proved to be a financial success as the company's revenue skyrocketed to ¥2.64 billion by April 1981.
Rohto Pharmaceutical Co. continued to acquire the management rights to The Mentholatum Company Inc in June 1988, thus completing the merge.




1999..The Food and Drug Administration has approved for marketing LIDODERM (Lidocaine patch 5%), a patch dermal delivery system codeveloped by TEIKOKU SEIYAKU CO., LTD. and HIND HEALTHCARE INC. of Fresno, California. LIDODERM is the first product the FDA has sanctioned specifically for the treatment of pain associated with postherpetic neuralgia. PHN results from nerve injury or damage during an outbreak of shingles, a reactivation of the herpes zoster virus that causes chicken pox. Kagawa prefecture-based Teikoku Seiyaku expects LIDODERM to be launched in the third quarter of this year. It will be imported by wholly owned TEIKOKU PHARMA USA, INC. and distributed by ENDO PHARMACEUTICALS INC. of Chadds Ford, Pennsylvania, another wholly owned subsidiary that Teikoku Seiyaku formed in 1997. As the first drug for hard-to-treat PHN-caused pain, LIDODERM sales could total $100 million, the Japanese maker of anti-inflammatory and analgesic patches estimates.

http://messages.finance.yahoo.com/St...=2&frt=2&off=1

you have got to be kidding! the same company that developed Lidoderm for Endo also developed Flector...check out the Teikoku USA website...this is crazy!

Teikoku was responsible for developing the first analgesic and anti-inflammatory plaster. Since then, we have expanded our portfolio. Here are some of the products that we have successfully developed:

Product: Flector EP® 2 (Diclofenac Epolamine)

Co-developed with IBSA, this hydrogel patch is marketed throughout Europe for minor sports injuries under various brand names—including Flector EP® and Voltapatch® by IBSA and Novartis respectively.

Product: Lidoderm® 1 (Lidocaine)

The first and only prescription hydrogel-patch approved in the United States for post-herpetic neuralgia (PHN). Teikoku partnered with Endo Pharmaceuticals to market the product in North America and with IBSA in Switzerland.

http://www.teikokuusa.com/marketed_rxs.php

dag u guys are LATE! We met the people from ISBA last Jan when launched and share that history during the detail. It's common knowledge to the Drs...I guess your company didnt tell YOU?! Yep, the money goes in the SAME pocket! Go figure. Now who you REALLY mad at? Go get it!!!!

We have known about this potential problem for some time...Old news.

All I can say is : AhhhhhsssssHoleeee.

Get it, and we are thee Butt of this joke folks.

When will this be decided? This would put the stock into freefall

Yeah, would have to stop selling Lido sometime in November I heard....I am looking for a new sales job now.

I can't believe that we would take this risk. This lectec company is worth like $15 million, can't we buy them?

Originally Posted by Anonymous

check this out...

Preliminary Injunction Against Endo possible $300 million hit 23-Jun-09 01:46 pm This stock is dead in the water till this is over

I wonder if Endo had any idea that this patch was infringing on the lectec patent. They were just so dang excited about the $100 mill potential in 1999... which is now $700 million annually ........the FDA exclusive approval runs out in 2015....total sales from 1999 through 2015 would be approx $10 billion x 3% = $300 million to Lectec or around $70 a share cash.




( Mentholatum who settled with lectec is also a Japanese owned company In 1974, the giant Japanese pharmaceutical company based in Osaka known as Rohto Pharmaceutical Co. set its eyes on The Mentholatum Company. In August 1975, it acquired the trademark rights to Mentholatum and began to sell the Mentholatum Ointment and Mentholatum Medicated Lip Stick, which proved to be a financial success as the company's revenue skyrocketed to ¥2.64 billion by April 1981.
Rohto Pharmaceutical Co. continued to acquire the management rights to The Mentholatum Company Inc in June 1988, thus completing the merge.




1999..The Food and Drug Administration has approved for marketing LIDODERM (Lidocaine patch 5%), a patch dermal delivery system codeveloped by TEIKOKU SEIYAKU CO., LTD. and HIND HEALTHCARE INC. of Fresno, California. LIDODERM is the first product the FDA has sanctioned specifically for the treatment of pain associated with postherpetic neuralgia. PHN results from nerve injury or damage during an outbreak of shingles, a reactivation of the herpes zoster virus that causes chicken pox. Kagawa prefecture-based Teikoku Seiyaku expects LIDODERM to be launched in the third quarter of this year. It will be imported by wholly owned TEIKOKU PHARMA USA, INC. and distributed by ENDO PHARMACEUTICALS INC. of Chadds Ford, Pennsylvania, another wholly owned subsidiary that Teikoku Seiyaku formed in 1997. As the first drug for hard-to-treat PHN-caused pain, LIDODERM sales could total $100 million, the Japanese maker of anti-inflammatory and analgesic patches estimates.

http://messages.finance.yahoo.com/St...=2&frt=2&off=1

This suks big- from yahoo Endo message board

On 29 May 2009 Mentholatum (Rohto) signed a settlement agreement with LecTec to release it from claims of patent infringement made by LecTec based on the general design of its topical analgesic patches under the Wellpatch brand. The Federal Court recognized the withdrawal of Mentholatum as a defendant on 5 June 2009. According to LecTec's 8-K filing the settlement amount was $600,000..................

This settlement suggests that LecTec's re-examined patents are sufficient to shake off counterattack....................

and that Mentholatum may have entered into a licensing agreement assuming they continue to sell this patch design. This judicial dismissal leaves four defendants: J&J (Ben Gay), Chattem (Icy Hot), Endo (Lidoderm) and Prince of Peace (Tiger Balm). Leaving aside the Rx Lidoderm patch and the minority player Tiger Balm, this leaves Ben Gay and Icy Hot, either one of which could have approached Hisamitsu for its patch technology which lies outside of the LecTec suit. Industry rumors suggest that J&J, after acquiring the Ben Gay line from Pfizer, may be looking to relaunch the Ben Gay line up. This could suggest conversion to Hisamitsu technology or a repositioning of the brand. The various legal manoeuvres in Federal court suggest stalling tactics on the part of the remaining defendants perhaps an effort to buy time while the FDA decides whether to "ban" topical patches from US monograph. All this suggests that J&J and Chattem may be looking to synchronize relaunches with the retail planogram cycle, awaiting the FDA ruling, preparing OTC NDA's to stay in the market, and/or talking to alternative Asian manufacturers such as Hitsamitsu. Recall that any traditional or non-traditional patch-like products in the market, although not part of this suit, would each require NDA's to remain in the market if FDA removes them from "free sale". In any event expect a major shift in manufacturers' market share, product offerings, and positionings coming later this year and next. See prior story below:


Taken together these events will conspire to create turbulence that is likely to change the face of this category. We estimate the regulatory grace period and the legal process will intersect in early 2011. In the meantime it is possible that a Federal Court order may stop sale of named patch products [Ben Gay, Icy Hot, Wellpatch, Tiger Balm, Capsaisin, Lidoderm] in mid-summer 2009. By now manufacturers should have made pro-active decisions about how to protect their brands. However, these two fact streams present a Catch-22 for these companies: how do you invest in a pre-emptive NDA for a final product if you are uncertain that you can own it(call Lectec to own it), or practice it, or afford the licensing fees?(Lectec will be reasonable) How exclusive will my supplier’s technology be?(Two Lectec re-examined patents)

Originally Posted by Anonymous

check this out...

Preliminary Injunction Against Endo possible $300 million hit 23-Jun-09 01:46 pm This stock is dead in the water till this is over

I wonder if Endo had any idea that this patch was infringing on the lectec patent. They were just so dang excited about the $100 mill potential in 1999... which is now $700 million annually ........the FDA exclusive approval runs out in 2015....total sales from 1999 through 2015 would be approx $10 billion x 3% = $300 million to Lectec or around $70 a share cash.




( Mentholatum who settled with lectec is also a Japanese owned company In 1974, the giant Japanese pharmaceutical company based in Osaka known as Rohto Pharmaceutical Co. set its eyes on The Mentholatum Company. In August 1975, it acquired the trademark rights to Mentholatum and began to sell the Mentholatum Ointment and Mentholatum Medicated Lip Stick, which proved to be a financial success as the company's revenue skyrocketed to ¥2.64 billion by April 1981.
Rohto Pharmaceutical Co. continued to acquire the management rights to The Mentholatum Company Inc in June 1988, thus completing the merge.




1999..The Food and Drug Administration has approved for marketing LIDODERM (Lidocaine patch 5%), a patch dermal delivery system codeveloped by TEIKOKU SEIYAKU CO., LTD. and HIND HEALTHCARE INC. of Fresno, California. LIDODERM is the first product the FDA has sanctioned specifically for the treatment of pain associated with postherpetic neuralgia. PHN results from nerve injury or damage during an outbreak of shingles, a reactivation of the herpes zoster virus that causes chicken pox. Kagawa prefecture-based Teikoku Seiyaku expects LIDODERM to be launched in the third quarter of this year. It will be imported by wholly owned TEIKOKU PHARMA USA, INC. and distributed by ENDO PHARMACEUTICALS INC. of Chadds Ford, Pennsylvania, another wholly owned subsidiary that Teikoku Seiyaku formed in 1997. As the first drug for hard-to-treat PHN-caused pain, LIDODERM sales could total $100 million, the Japanese maker of anti-inflammatory and analgesic patches estimates.

http://messages.finance.yahoo.com/St...=2&frt=2&off=1

I hope this is over soon!

Originally Posted by Anonymous

This suks big- from yahoo Endo message board

On 29 May 2009 Mentholatum (Rohto) signed a settlement agreement with LecTec to release it from claims of patent infringement made by LecTec based on the general design of its topical analgesic patches under the Wellpatch brand. The Federal Court recognized the withdrawal of Mentholatum as a defendant on 5 June 2009. According to LecTec's 8-K filing the settlement amount was $600,000..................

This settlement suggests that LecTec's re-examined patents are sufficient to shake off counterattack....................

and that Mentholatum may have entered into a licensing agreement assuming they continue to sell this patch design. This judicial dismissal leaves four defendants: J&J (Ben Gay), Chattem (Icy Hot), Endo (Lidoderm) and Prince of Peace (Tiger Balm). Leaving aside the Rx Lidoderm patch and the minority player Tiger Balm, this leaves Ben Gay and Icy Hot, either one of which could have approached Hisamitsu for its patch technology which lies outside of the LecTec suit. Industry rumors suggest that J&J, after acquiring the Ben Gay line from Pfizer, may be looking to relaunch the Ben Gay line up. This could suggest conversion to Hisamitsu technology or a repositioning of the brand. The various legal manoeuvres in Federal court suggest stalling tactics on the part of the remaining defendants perhaps an effort to buy time while the FDA decides whether to "ban" topical patches from US monograph. All this suggests that J&J and Chattem may be looking to synchronize relaunches with the retail planogram cycle, awaiting the FDA ruling, preparing OTC NDA's to stay in the market, and/or talking to alternative Asian manufacturers such as Hitsamitsu. Recall that any traditional or non-traditional patch-like products in the market, although not part of this suit, would each require NDA's to remain in the market if FDA removes them from "free sale". In any event expect a major shift in manufacturers' market share, product offerings, and positionings coming later this year and next. See prior story below:


Taken together these events will conspire to create turbulence that is likely to change the face of this category. We estimate the regulatory grace period and the legal process will intersect in early 2011. In the meantime it is possible that a Federal Court order may stop sale of named patch products [Ben Gay, Icy Hot, Wellpatch, Tiger Balm, Capsaisin, Lidoderm] in mid-summer 2009. By now manufacturers should have made pro-active decisions about how to protect their brands. However, these two fact streams present a Catch-22 for these companies: how do you invest in a pre-emptive NDA for a final product if you are uncertain that you can own it(call Lectec to own it), or practice it, or afford the licensing fees?(Lectec will be reasonable) How exclusive will my supplier’s technology be?(Two Lectec re-examined patents)